期刊文献+

化疗序贯厄洛替尼治疗二线厄洛替尼耐药晚期非小细胞肺癌的临床疗效和安全性 被引量:2

Treatment outcomes and safety of sequential administration of erlotinib following chemotherapy in patients with erlotinib(as second-line treatment)-resistant advanced non-small cell lung cancer
原文传递
导出
摘要 目的:观察二线厄洛替尼耐药后应用化疗序贯厄洛替尼治疗晚期非小细胞肺癌的疗效和安全性。方法:回顾性分析30例ⅢB~Ⅳ期二线厄洛替尼耐药后缓慢进展的晚期非小细胞肺癌患者的资料,其中15例接受1个周期化疗(培美曲塞联合顺铂)后序贯厄洛替尼治疗(A组),另15例仅接受化疗(培美曲塞联合顺铂)(B组)。观察两组的近期疗效和不良反应,并进行生存分析。结果:A组和B组的客观缓解率分别为13.3%(2/15)和6.7%(1/15)(P=1.000),疾病控制率分别为40.0%(6/15)和20.0%(3/15)(P=0.426),中位无进展生存期分别为6.0和4.0个月(P=0.001)。两组不良反应发生率差异无统计学意义。结论:化疗序贯厄洛替尼治疗二线厄洛替尼耐药晚期非小细胞肺癌患者具有较好的疗效,且不良反应可以耐受。 Objective: To observe the therapeutic efficacy and safety of sequential administration of erlotinib. following chemotherapy in patients with erlotinib (as second-line treatment)-resistant advanced NSCLC (non-small cell lung cancer). Methods: Thirty stages ⅢB-Ⅳ NSCLC patients with gradual progression after erlotinib treatment as second-line therapy were retrospectively reviewed. Of the 30 patinets, 15 patinets (group A) received one cycle of chemotherapy (pemetrexed plus cisplatin) followed by erlotinib, the remaining 15 patinets (group B) received chemotherapy alone (pemetrexed plus cisplatin). The short-term response and side effects were observed and the survival was analyzed. Results: The objective response rates of group A and group B were 13.3% (2/15) and 6.7% (1/15), respectively (P = 1.000), and the disease control rates were 40.0% (6/15) and 20.0% (3/15), respectively (P = 0.426). The median progression-free survival of group A and group B were 6.0 and 4.0 months, respectively (P = 0.001). There were no significant differences in the rates of side effects between the two groups. Conclusion: The administration of erlotinib following chemotherapy may offer benefits to the patients with erlotinib (as second-line treatment)-resistant advanced NSCLC. This treatment is also generally tolerable .
出处 《肿瘤》 CAS CSCD 北大核心 2013年第11期1002-1007,共6页 Tumor
关键词 非小细胞肺 厄洛替尼 抗肿瘤联合化疗方案 耐药 治疗结果 Carcinoma, non-small cell lung Erlotinib Antineoplastic combined chemotherapy protocol Resistance Treatment outcomes
  • 相关文献

二级参考文献53

  • 1赵俊卿,李云峰,杨之斌.肿瘤细胞发生细胞上皮-间质转变机制的研究[J].肿瘤,2010,30(10):890-893. 被引量:27
  • 2Govindan R,Page N,Morgensztern D,et al.Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemioiogic,and results database.J Clin Oncol,2006,24:4539-4544. 被引量:1
  • 3Spira A,Ettinger DS.Multidisciplinary management of lung cancer.N Engt J Med,2004,350:379-392. 被引量:1
  • 4Shepherd FA,Rodrigues Pereira J,Ciuleanu T,et al.Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med,2005,353:123-132. 被引量:1
  • 5Kim ES,Hirsh V,Mok T,et al.Gefitinib versus docetsxel in previously treated non-small-cell lung cancer (INTEREST):a randomised phase Ⅲ trial.Lancet,2008,372:1809-1818. 被引量:1
  • 6Maruyama R,Nishiwaki Y,Tamura T,et al.Phase Ⅲ study,V-15-32,of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.J Clin Oncol,2008,26:4244-4252. 被引量:1
  • 7Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma.N Engl J Med,2009,361:947-957. 被引量:1
  • 8Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy.J Clin Oncol,2004,22:1589-1597. 被引量:1
  • 9Cho BC,Im CK,Park MS,et al.Phase Ⅱ study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.J Clin Oncol,2007,25:2528-2533. 被引量:1
  • 10Kaira K,Naito T,Takahashi T,et al.Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.Lung Cancer,2010,68:99-104. 被引量:1

共引文献110

同被引文献29

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部